Defining the Added Value of 99mTc-MIBI SPECT/CT to Conventional Cross-Sectional Imaging in the Characterization of Enhancing Solid Renal Masses

Sheikhbahaei, Sara; Jones, Christopher S.; Porter, Kristin K.; Rowe, Steven P.; Gorin, Michael A.; Baras, Alex; Pierorazio, Phillip M.; Ball, Mark W.; Higuchi, Takahiro; Johnson, Pamela T.; Solnes, Lilja B.; Epstein, Jonathan I.; Allaf, Mohamad E.; Javadi, Mehrbod S.

doi:10.1097/rlu.0000000000001534

Cited by 33 publications

(40 citation statements)

References 31 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 A secondary analysis of this study illustrated that incorporating 99m Tc-sestamibi SPECT/CT into the pre-operative work-up of renal lesions significantly augmented confidence in characterizing renal masses as benign or malignant. 19 Following these reports, investigators at the Karolinska University Hospital in Stockholm, Sweden found similar results in a study of 27 patients with 31 tumours imaged with 99m Tc-sestamibi SPECT/CT prior to either surgery or biopsy. In this study, 11/12 (91.6%) oncocytomas and 3/3 (100%) HOCTs were identified with this imaging test, with only two false positives (one papillary RCC that was described as having "slight" uptake and one angiomyolipoma).…”

mentioning

confidence: 73%

99mTc-sestamibi SPECT/CT for the characterization of renal masses: a pictorial guide

Campbell

Tzortzakakis

Javadi

et al. 2018

The British Journal of Radiology

View full text Add to dashboard Cite

In parallel to the increased utilization of cross-sectional imaging, the incidence of small renal masses has steadily risen in recent years. At the present time, anatomical imaging techniques are limited in their ability to differentiate benign from malignant renal masses. Moreover, renal mass biopsy has a high non-diagnostic rate, poor negative-predictive ability, and carries potential risks as well as substantial costs. As a result, benign renal masses are often unnecessarily resected for the false presumption of cancer. Tc-sestamibi single photon emission computed tomography/computed tomography (SPECT/CT) is a molecular imaging test that allows for the differentiation of benign renal oncocytomas and hybrid oncocytomic/chromophobe tumours apart from malignant renal cell carcinomas on the basis of differences in mitochondrial content as well as multidrug resistant pump expression. Herein, we review the principles ofTc-sestamibi SPECT/CT administration and image interpretation for the purpose of renal mass characterization.

show abstract

mentioning

confidence: 73%

99mTc-sestamibi SPECT/CT for the characterization of renal masses: a pictorial guide

Campbell

Tzortzakakis

Javadi

et al. 2018

The British Journal of Radiology

View full text Add to dashboard Cite

show abstract

“…Molecular imaging with 99m technetium–sestamibi single photon emission computed tomography/computed tomography ( 99m Tc-MIBI SPECT/CT) has also been used to differentiate oncocytomas and indolent hybrid oncocytic/chromophobe tumours from other more aggressive malignant small renal tumours. The former contain numerous and dense cellular mitochondria and therefore demonstrate “hot” radiotracer uptake relative to the ipsilateral renal parenchyma, whereas the latter appear “cold” [ 70 , 71 ]. Sheikhbahaei et al evaluated the diagnostic accuracy of standard pre-operative CT, MRI and 99m Tc-MIBI SPECT/CT in 48 patients with small renal masses undergoing partial or radical nephrectomy.…”

Section: Resultsmentioning

confidence: 99%

“…Sheikhbahaei et al evaluated the diagnostic accuracy of standard pre-operative CT, MRI and 99m Tc-MIBI SPECT/CT in 48 patients with small renal masses undergoing partial or radical nephrectomy. The area under the receiver operator characteristic curve for the differentiation of benign from malignant masses was 0.60 for CT and MRI alone, increasing to 0.85 with the addition of 99m Tc-MIBI SPECT/CT [ 71 ]. Quantitative techniques for image analysis may enable increased accuracy and use of 99m Tc-MIBI SPECT/CT in future [ 72 ].…”

Section: Resultsmentioning

confidence: 99%

Imaging for the diagnosis and response assessment of renal tumours

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Out of these nine patients, pathology report was compatible with oncocytoma in seven patients and chromophobe RCC in two patients. Five patients with negative Tc-99m MIBI SPECT/CT were confirmed to have RCC in the postoperative period (32).…”

Section: Tc-99m Myocardial Perfusion Imaging Test Spect/ctmentioning

confidence: 99%

Nuclear Medicine Applications in Diagnosis of Urological Tumors

Araz¹,

Ürün²

2019

uob

View full text Add to dashboard Cite

Except for prostate carcinoma, there is limited data in the literature on the role of nuclear imaging methods in the management of urological cancers. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is generally the most widely used method in oncological imaging. However, the diagnostic power of this radiopharmaceutical in urological tumors is weakened partially due to its physiological urinary excretion. For this reason, some other 18F-labeled molecules, especially Ga-68 prostate-specific membrane antigen for prostate cancer and 18F-sodium fluoride for bone metastases, have recently gained importance. In addition, characterization of renal masses with Tc-99m methoxy isobutyl isonitrile (MIBI), a nonspecific tumor agent, and detection of bone metastases with whole-body Tc-99m methylene diphosphonate (MDP) bone scintigraphy are still used. In this review, scintigraphic methods and PET/CT imaging used in diagnosis and follow-up of urological tumors will be discussed.

show abstract

Defining the Added Value of 99mTc-MIBI SPECT/CT to Conventional Cross-Sectional Imaging in the Characterization of Enhancing Solid Renal Masses

Abstract: Preoperative Tc-MIBI SPECT/CT enhances the performance of conventional imaging, improving the characterization of benign histologies and lowering the possibility of misclassification.

Cited by 33 publications

References 31 publications

99mTc-sestamibi SPECT/CT for the characterization of renal masses: a pictorial guide

99mTc-sestamibi SPECT/CT for the characterization of renal masses: a pictorial guide

Imaging for the diagnosis and response assessment of renal tumours

Nuclear Medicine Applications in Diagnosis of Urological Tumors

Contact Info

Product

Resources

About